Integrated Advisors Network’s BioMarin Pharmaceuticals BMRN Stock Holding History

Integrated Advisors Network’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,137	Closed	-$224K	–	726
2025 Q3	$224K	Sell	4,137 -930	-18%	-$53.2K	0.01%	724
2025 Q2	$279K	Buy	5,067 +1,067	+27%	+$62.8K	0.01%	639
2025 Q1	$283K	Buy	4,000 +876	+28%	+$58.9K	0.01%	598
2024 Q4	$205K	Sell	3,124 -2,138	-41%	-$143K	0.01%	667
2024 Q3	$370K	Buy	5,262 +1,876	+55%	+$157K	0.02%	548
2024 Q2	$279K	Sell	3,386 -53	-2%	-$4.41K	0.01%	585
2024 Q1	$300K	Sell	3,439 -94	-3%	-$8.41K	0.02%	599
2023 Q4	$341K	Buy	3,533 +206	+6%	+$18.2K	0.02%	525
2023 Q3	$294K	Buy	3,327 +25	+0.8%	+$2.22K	0.02%	545
2023 Q2	$286K	Hold	3,302	–	–	0.02%	556
2023 Q1	$321K	Buy	3,302 +130	+4%	+$13.5K	0.02%	530
2022 Q4	$328K	Buy	+3,172	New	+$298K	0.02%	497

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Integrated Advisors Network's BMRN Position: Q4 2025 in Review

Integrated Advisors Network sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,137 shares — an estimated $224K sold.

Integrated Advisors Network first reported a position in BMRN in Q4 2022 and held it in 12 quarters. The position peaked at $370K in Q3 2024. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Integrated Advisors Network reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Integrated Advisors Network sold 4,137 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $224K.
Integrated Advisors Network first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 12 quarters.
Integrated Advisors Network's BioMarin Pharmaceuticals position peaked at $370K in Q3 2024.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Integrated Advisors Network's 13F filing for Q4 2025, filed 17 Feb 2026.